Our hypothesis for the antitumor effects of the combination therapy with NextA and anti-CD47 is that targeting both sides of this innate immune checkpoint has a beneficial effect for antitumor efficacy: downregulation of SIRPα on macrophages through HDAC6 inhibition and blockade of CD47 on tumor cells through the use of blocking antibodies. This evidence concerns the gene SIRPA and neoplasm.